腹膜后脂肪肉瘤的研究进展  

Progress of retroperitoneal liposarcoma

作　　者：张皓凡 郭建昇[2] Zhang Haofan;Guo Jiansheng(The First Clinical Medical College,Shanxi Medical University,Taiyuan 030012,China;Department of Gastrointestinal Surgery,the First Hospital of Shanxi Medical University,Taiyuan 030001,China)

机构地区：[1]山西医科大学第一临床医学院,太原030012 [2]山西医科大学第一医院胃肠外科,太原030001

出　　处：《肿瘤研究与临床》2025年第3期236-240,共5页Cancer Research and Clinic

摘　　要：腹膜后脂肪肉瘤生长具有隐匿性,早期一般无明显临床症状及体征。原发性腹膜后脂肪肉瘤的临床及病理特点不明显,导致其早期诊断困难,手术切除率低,术后复发率较高。腹膜后脂肪肉瘤放化疗疗效仍存在争议,近年来关于基因组学及免疫组织化学相关的研究逐渐增多,以此为基础衍生出的相关靶向治疗也显示出较好的效果,为腹膜后脂肪肉瘤的诊疗提供了新思路。The growth of retroperitoneal liposarcoma is occult,and generally there are no obvious clinical symptoms and signs in the early stage.The clinical and pathological features of primary retroperitoneal liposarcoma are not obvious,which lead to the difficulty of early diagnosis,low surgical resection rate and high postoperative recurrence rate.The effect of radiotherapy and chemotherapy on retroperitoneal liposarcoma is still controversial.In recent years,the researches of genomics and immunohistochemistry have gradually increased,and the related targeted therapies derived from these researches have also shown some preferable results,which provide new ideas for the diagnosis and treatment of retroperitoneal liposarcoma.

关 键 词：脂肪肉瘤 腹膜后间隙 基因组 分子生物学 诊断 治疗 预后 

分 类 号：R735.4[医药卫生—肿瘤]